Dr. Shuch and Dr. Calais have opened the CA NINE trial, which is a prospective comparison of contrast-enhanced CT against 89 Zr-TLX250 PET for the imaging-based detection of recurrent clear cell renal ...

Adding casdatifan to Cabometyx therapy showed encouraging activity and was generally well tolerated in previously treated ...

Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.

Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell ...

A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, ...

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient ...

Genetic predisposition plays an important role in the pathogenesis of renal cell carcinoma. The prevalence of pathogenic/likely pathogenic (P/LP) in patients with renal cell cancer (RCC) is highly ...

To enhance the understanding of the tumor microenvironment of hepatocellular carcinoma, the authors employed an integrative single-cell analysis of posttranslational modifications, identifying ...

(“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that the medical journal Nature has published findings by a team of physician-scientists ...

The three major histopathological subtypes of RCC are clear cell carcinoma (ccRCC), papillary carcinoma (pRCC), and chromophobe renal cell carcinoma (chrRCC). Studies have reported that ccRCC has the ...